- Home
- JWEL vs APVO Comparison
JWEL vs APVO Comparison
Compare JWEL & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JWEL
- APVO
- Stock Information
- Founded
- JWEL 2012
- APVO 2016
- Country
- JWEL China
- APVO United States
- Employees
- JWEL N/A
- APVO N/A
- Industry
- JWEL Other Consumer Services
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- JWEL Consumer Discretionary
- APVO Health Care
- Exchange
- JWEL Nasdaq
- APVO Nasdaq
- Market Cap
- JWEL 4.1M
- APVO 4.1M
- IPO Year
- JWEL 2021
- APVO N/A
- Fundamental
- Price
- JWEL $1.88
- APVO $1.61
- Analyst Decision
- JWEL
- APVO Strong Buy
- Analyst Count
- JWEL 0
- APVO 1
- Target Price
- JWEL N/A
- APVO $5,920.00
- AVG Volume (30 Days)
- JWEL 13.5K
- APVO 162.7K
- Earning Date
- JWEL 05-09-2025
- APVO 11-06-2025
- Dividend Yield
- JWEL N/A
- APVO N/A
- EPS Growth
- JWEL N/A
- APVO N/A
- EPS
- JWEL N/A
- APVO N/A
- Revenue
- JWEL $132,981,531.00
- APVO N/A
- Revenue This Year
- JWEL N/A
- APVO N/A
- Revenue Next Year
- JWEL N/A
- APVO N/A
- P/E Ratio
- JWEL N/A
- APVO N/A
- Revenue Growth
- JWEL N/A
- APVO N/A
- 52 Week Low
- JWEL $1.20
- APVO $1.54
- 52 Week High
- JWEL $3.71
- APVO $381.10
- Technical
- Relative Strength Index (RSI)
- JWEL 43.81
- APVO 28.32
- Support Level
- JWEL $1.75
- APVO $1.56
- Resistance Level
- JWEL $2.06
- APVO $1.73
- Average True Range (ATR)
- JWEL 0.08
- APVO 0.14
- MACD
- JWEL 0.01
- APVO 0.02
- Stochastic Oscillator
- JWEL 40.84
- APVO 11.29
About JWEL Jowell Global Ltd.
Jowell Global Ltd is a cosmetics, health, nutritional supplements, and household products e-commerce platform in China. The company offers its branded products to customers and also sells and distributes products from other companies on its platform. In addition, it allows third parties to open their stores on its platform for a service fee based on their sales revenues generated from their online stores and provides them with information about market needs, enabling them to manage their sales effort, as well as an effective platform to promote their brands. The company currently operates under four sales channels: Online Direct Sales, Authorized Retail Store Distribution, Third-party Merchants, and Live streaming marketing. Geographically, it generates all of its revenue from the PRC.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.